東華大學圖書館 |

Using CSF Biomarkers to Understand Mechanisms of Behavioral Changes and Effects of Drug Treatment in Dementia.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Using CSF Biomarkers to Understand Mechanisms of Behavioral Changes and Effects of Drug Treatment in Dementia./
作者:	Bloniecki Kallio, Victor.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	105 p.
附註:	Source: Dissertations Abstracts International, Volume: 82-09, Section: B.
Contained By:	Dissertations Abstracts International82-09B.
標題:	Pharmacology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28420790
ISBN:	9798582530060

Using CSF Biomarkers to Understand Mechanisms of Behavioral Changes and Effects of Drug Treatment in Dementia.
Bloniecki Kallio, Victor.

Using CSF Biomarkers to Understand Mechanisms of Behavioral Changes and Effects of Drug Treatment in Dementia. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 105 p.

Source: Dissertations Abstracts International, Volume: 82-09, Section: B.

Thesis (Ph.D.)--Karolinska Institutet (Sweden), 2020.

This item must not be sold to any third party vendors.

Dementia is affecting millions of people around the world, and the global prevalence will continuously rise. Neuropsychiatric symptoms (NPS) in dementia are frequent and constitute a key driving force in the disease burden for both patients,families, caregivers and society. The clinical presentation includes symptoms such as agitation, depression, anxiety, apathy and irritability, which are highly frequent in patients with dementia. NPS have a significant negative impact on a patient's ability to perform activities of daily living and also contribute largely to the disease-associated health care costs. Current knowledge of the pathophysiological mechanisms causing NPS is lacking, and improved understanding of these processes is of great importance in order to improve treatment of NPS.The main purpose of this thesis was to examine the pathophysiological mechanisms underlying NPS by investigating their associations to cerebrospinal fluid (CSF)biomarkers reflecting core Alzheimer's dementia (AD) pathology (phosphorylated-tau[P-tau], total-Tau [T-tau], β-amyloid 1-42 [Aβ-1-42]), synaptic degeneration(neurogranin [Ng], growth-associated protein 43 [GAP-43]) and axonal degeneration(neurofilament light protein [NFL]) in patients with dementia. Secondary aims included investigation of how treatment with an acetylcholinesterase inhibitor(AChEI) (Galantamine) or antipsychotic (Risperidone) impacts both the clinical symptoms and CSF biomarker patterns. In the first study, we showed that agitation correlated with increased levels of P-tau and T-tau in CSF, but not with Aβ-1-42.Thus, suggesting an association between agitation and tau-mediated pathology. The second study was an open randomized clinical trial comparing the efficacy of Galantamine and Risperidone for the treatment of agitation in patients with dementia. Both drugs were effective in reducing levels of agitation. However, Risperidone was more efficient at decreasing NPS, although at the cost of lower tolerability and increased rate of adverse events. In the third study, we showed that treatment with Risperidone, but not Galantamine, was associated with a decrease of CSF Aβ-1-42. Indicating a potential association between Risperidone and progression of amyloid pathology. In the fourth study, we investigated the association between NPS and biomarkers for synaptic degeneration (Ng, GAP-43) and axonal degeneration (NFL). Levels of Ng, GAP-43 and NFL did not differ between AD patients with high vs low levels of NPS. We also found associations between CSF markers for synaptic (Ng, GAP-43) and axonal degeneration (NFL) with NPS,especially of the psychotic spectrum, in patients with vascular dementia (VaD).In conclusion, our results implicate tau-mediated pathology and synaptic dysfunction as contributing components to the presence of NPS in AD and VaD. In contrast,no clear evidence supporting the role of amyloid pathology in NPS was observed.Interestingly, treatment with Risperidone affected CSF Aβ-1-42 levels, providing a possible pathway for the previously observed association between use of antipsychotics and accelerated rate of cognitively decline seen in patients with dementia.

ISBN: 9798582530060Subjects--Topical Terms:

634543
Pharmacology.
Subjects--Index Terms:

Dementia

Using CSF Biomarkers to Understand Mechanisms of Behavioral Changes and Effects of Drug Treatment in Dementia.
LDR:04408nmm a2200349 4500 001 2346143
005 20220613065113.5
008 241004s2020 ||||||||||||||||| ||eng d
020 $a 9798582530060
035 $a (MiAaPQ)AAI28420790
035 $a (MiAaPQ)Karolinska_1061647116
035 $a AAI28420790
040 $a MiAaPQ $c MiAaPQ
100 1 $a Bloniecki Kallio, Victor. $3 3685190
245 1 0 $a Using CSF Biomarkers to Understand Mechanisms of Behavioral Changes and Effects of Drug Treatment in Dementia.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 105 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-09, Section: B.
500 $a Includes supplementary digital materials.
500 $a Advisor: Freund-Levi, Yvonne;Aarsland, Dag;Blennow, Kaj.
502 $a Thesis (Ph.D.)--Karolinska Institutet (Sweden), 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Dementia is affecting millions of people around the world, and the global prevalence will continuously rise. Neuropsychiatric symptoms (NPS) in dementia are frequent and constitute a key driving force in the disease burden for both patients,families, caregivers and society. The clinical presentation includes symptoms such as agitation, depression, anxiety, apathy and irritability, which are highly frequent in patients with dementia. NPS have a significant negative impact on a patient's ability to perform activities of daily living and also contribute largely to the disease-associated health care costs. Current knowledge of the pathophysiological mechanisms causing NPS is lacking, and improved understanding of these processes is of great importance in order to improve treatment of NPS.The main purpose of this thesis was to examine the pathophysiological mechanisms underlying NPS by investigating their associations to cerebrospinal fluid (CSF)biomarkers reflecting core Alzheimer's dementia (AD) pathology (phosphorylated-tau[P-tau], total-Tau [T-tau], β-amyloid 1-42 [Aβ-1-42]), synaptic degeneration(neurogranin [Ng], growth-associated protein 43 [GAP-43]) and axonal degeneration(neurofilament light protein [NFL]) in patients with dementia. Secondary aims included investigation of how treatment with an acetylcholinesterase inhibitor(AChEI) (Galantamine) or antipsychotic (Risperidone) impacts both the clinical symptoms and CSF biomarker patterns. In the first study, we showed that agitation correlated with increased levels of P-tau and T-tau in CSF, but not with Aβ-1-42.Thus, suggesting an association between agitation and tau-mediated pathology. The second study was an open randomized clinical trial comparing the efficacy of Galantamine and Risperidone for the treatment of agitation in patients with dementia. Both drugs were effective in reducing levels of agitation. However, Risperidone was more efficient at decreasing NPS, although at the cost of lower tolerability and increased rate of adverse events. In the third study, we showed that treatment with Risperidone, but not Galantamine, was associated with a decrease of CSF Aβ-1-42. Indicating a potential association between Risperidone and progression of amyloid pathology. In the fourth study, we investigated the association between NPS and biomarkers for synaptic degeneration (Ng, GAP-43) and axonal degeneration (NFL). Levels of Ng, GAP-43 and NFL did not differ between AD patients with high vs low levels of NPS. We also found associations between CSF markers for synaptic (Ng, GAP-43) and axonal degeneration (NFL) with NPS,especially of the psychotic spectrum, in patients with vascular dementia (VaD).In conclusion, our results implicate tau-mediated pathology and synaptic dysfunction as contributing components to the presence of NPS in AD and VaD. In contrast,no clear evidence supporting the role of amyloid pathology in NPS was observed.Interestingly, treatment with Risperidone affected CSF Aβ-1-42 levels, providing a possible pathway for the previously observed association between use of antipsychotics and accelerated rate of cognitively decline seen in patients with dementia.
590 $a School code: 0658.
650 4 $a Pharmacology. $3 634543
653 $a Dementia
653 $a Drug treatment
653 $a CSF biomarkers
690 $a 0419
710 2 $a Karolinska Institutet (Sweden). $3 3557748
773 0 $t Dissertations Abstracts International $g 82-09B.
790 $a 0658
791 $a Ph.D.
792 $a 2020
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28420790